natgillin/translations-raw huggingface dataset:
the lysine residue, corresponding to the position 860 in the sequence of the native CyaA of Bordetella pertussis as defined in SEQ ID NO: 1, is substituted by an arginine residue, said fragment having the capacity of the CyaA protein of Bordetella pertussis to bind to the CD11b/CD18 receptor of cells expressing the same, the capacity to translocate its N-terminal adenylate cyclase enzyme domain into said cells and having a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin; or 
ostatak lizina, koji odgovara položaju 860 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, zamijenjen je argininom, taj fragment ima sposobnost CyaA proteina Bordetella pertussis za vezanje na CD11b/CD18 receptor stanica koje imaju taj receptor, sposobnost translokacije (premještanja) svoje N-terminalne domene enzima adenilat ciklaze u te stanice i aktivnost stvaranja pora koja je smanjenja ili potisnuta u odnosu na nativni CyaA toksin; ili
the substitution of the glutamic acid residue, corresponding to the position 570 in the sequence of the native CyaA of Bordetella pertussis as defined in SEQ ID NO: 1, by a glutamine residue; 
zamjeni ostatka glutaminske kiseline, koji odgovara položaju 570 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, glutaminom;
the substitution of the lysine residue, corresponding to the position 860 in the sequence of the native CyaA of Bordetella pertussis as defined in SEQ ID NO: 1, by an arginine residue; and 
zamjeni ostatka lizina, koji odgovara položaju 860 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, argininom; i
from 1 to 50 additional substitutions; 
od 1 do 50 dodatnih zamjena;
Polypeptide according to claim 1, wherein said fragment is at least 900, 1000, 1100, 1200, 1300, 1400, 1500 or 1600 amino acid residues of SEQ ID NO:1, in size. 
Polipeptid prema zahtjevu 1, gdje je taj fragment veličine od barem 900, 1000, 1100, 1200, 1300, 1400, 1500 ili 1600 aminokiselinskih ostataka iz SEQ ID NO:1.
Polypeptide derivative according to any one of claims 8 to 10, which is a recombinant polypeptide wherein the amino acid sequence of each of said molecule(s) suitable for eliciting an immune response is inserted into a permissive site of said polypeptide, provided that the capacity of said polypeptide to translocate its N-terminal adenylate cyclase enzyme domain into CD11b/CD18 expressing cells is preserved. 
Polipeptidni derivat prema bilo kojem od zahtjeva 8 do 10, koji je rekombinantni polipeptid gdje je aminokiselinska sekvenca svake od molekula prikladnih za izazivanje imunog odgovora umetnuta na dopustivo mjesto tog polipetida, uz uvjet očuvanja sposobnosti tog polipeptida da premjesti svoju N-terminalnu domenu enzima adenilat ciklaze u stanice koje proizvode CD11b/CD18.
An antibody or a functional fragment of same, said functional fragment being selected among the fragments Fv, Fab, (Fab')2, Fab', scFv, scFv-Fc and diabodies, capable of inhibiting activation of CXCR4, characterized in that the said antibody is selected in the group consisting of: 
Antitijelo ili njegov funkcionalni fragment, a rečeni funkcionalni fragement odabran je od sljedećih fragmenata: Fab, (Fab’)2, Fab’, scFv, scFv-Fc te specifična dvostruka antitijela (engl. diabodies), koji mogu inhibirati aktivaciju CXCR4, naznačeno time da je rečeno antitijelo odabrano iz sljedeće skupine:
An isolated nucleic acid characterized in that the said isolated nucleic acid is a nucleic acid, DNA or RNA, coding for an antibody according to one of the claims 5 or 8. 
Izolirana nukleinska kiselina, naznačena time da rečena izolirana nukleinska kiselina, DNA ili RNA, kodira za antitijelo prema jednom od patentnih zahtjeva 5 ili 8.
A pharmaceutical composition according to claim 15, characterized in that it comprises, in addition, as a combination product for use in a simultaneous, separated or extended fashion, an anti-tumor antibody other that an antibody directed against CXCR4. 
Farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time da dodatno kao kombinacijski ili konjugirani produkt za istodobnu, odvojenu ili produljenu upotrebu sadrži antitumorsko antitijelo koje nije antitijelo usmjereno na CXCR4.
An antibody or a functional fragment of same, and/or a composition to according to the use of claim 20, characterized in that said cancer is a cancer selected among prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, multiple myeloma, ovarian cancer, pancreatic cancer and colon cancer. 
Antitijelo ili njegov funkcionalni fragment i/ili pripravak prema patentnom zahtjevu 20, naznačeno time da je rečeni karcinom odabran od sljedećih: karcinom prostate, osteokarcinom, karcinom pluća, karcinom dojke, karcinom endometrija, multipla mieloma, karcinom jajnika, karcinom pankreasa i karcinom crijeva.
Device as claimed in claim 1 or 2, characterized in that the winding core (3) is provided with a slot (7) for attaching a first outer end (2a) of the belt-like object to the winding core (3). 
Uređaj prema Zahtjevu 1 ili 2, naznačen time, što je na jezgri (3) za namotavanje izveden prorez (7) za pričvršćivanje prvog vanjskog kraja (2a) predmeta u obliku trake za jezgru (3) za namotavanje.
Device as claimed in claim 6, characterized in that the engaging means are provided with a third outward protruding third part (8d) extending at least along a part of the engaging means which third protruding part can be at least partially inserted into a space (8e) formed by mutually co-acting second protruding parts (12,12') provided for this purpose on the drum. 
Uređaj prema Zahtjevu 6, naznačen time, što sredstvo za pokretanje posjeduje treći ka vani izbočeni dio (8d) koji se pruža najmanje duž dijela sredstva za pokretanje, gdje treći izbočeni dio (8d) može najmanje djelomično biti umetnut u prostor (8e) sačinjen od strane izbočenih uzajamno sudjelujućih drugih dijelova (12, 12’) izvedenih radi ovoga na bubnju.
Device as claimed in any of the claims 1-7, characterized in that at least one part (4c,4c') of the drum (4) adjacent to the second opening (6b) is movable, preferably resiliently, relative to the rest of the drum (4). 
Uređaj prema bilo kojem od Zahtjeva 1 do 7, naznačen time, što je najmanje jedan od dijelova (4c, 4c’) bubnja (4) koji se nalaze neposredno do drugog otvora (6b) izveden kao pokretan, poželjno elastično pokretan, relativno u odnosu na ostatak bubnja (4).
Method as claimed in claim 11, characterized in that the first outer end of the belt-like object is attached to the winding core by insertion thereof into a slot (7) arranged for this purpose in the winding core. 
Postupak prema Zahtjevu 11, naznačen time, što je prvi vanjski kraj predmeta u obliku trake ili remena pričvršćen za jezgru umetanjem u prorez (7) izveden na jezgri.
Method as claimed in any of the claims 11-12, characterized in that the winding core (3) is then taken out of the receiving space (5) via the first opening (6a) wherein the wound belt-like object remains behind in the receiving space (5). 
Postupak prema Zahtjevu 12, naznačen time, što se jezgra (3) zatim uklanja iz prihvatnog prostora (5) kroz prvi otvor (6a) pri čemu namotani predmet u obliku trake ili remena ostaje odložen u unutrašnjosti prihvatnog prostora (5).
Method as claimed in any of the claims 11-14, characterized in that the method also comprises of subsequently taking the wound belt-like object out of the receiving space via the second opening wherein at least one part (4c,4c') of the drum adjacent to the second opening is moved relative to the rest of the drum, which at least one part is for this purpose movable, preferably resiliently, relative to the rest of the drum. 
Postupak prema bilo kojem od Zahtjeva 11 do 14, naznačen time, što postupak također obuhvaća i kasnije izdavanje namotanog predmeta u obliku trake ili remena iz prihvatnog prostora njegovim izvlačenjem kroz drugi otvor gdje je najmanje jedan od dijelova (4c, 4c’) bubnja koji su izvedeni odmah do drugog otvora pokretljiv, prvenstveno elastično pokretljiv, u odnosu na ostatak bubnja.
The medicament as claimed in any of claims 15 to 17, wherein the medicament is applied before and/or during and/or after treatment with at least one additional pharmacologically active substance. 
Medikament prema bilo kojem zahtjevu 15 do 17, naznačen time da se medikament primjenjuje prije i/ili tijekom i/ili nakon tretmana sa najmanje jednom dodatnom farmakološki aktivnom tvari.
heating up the resulting dispersion or solution of step (b) to elevated temperature T1, preferably 30° C to 95° C, more preferably 50° C, optionally under stirring, stirring until crystallization begins and continuing stirring at room temperature until completion of the crystallization process, 
grijanje dobivene disperzije ili otopine iz koraka (b) na povišenoj temperaturi T1, poželjno 30° C do 95° C, poželjnije 50° C, proizvoljno uz miješanje, te miješanje do početka kristalizacije i nastavak miješanja kod sobne temperature sve do okončanja postupka kristalizacije,
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride anhydrate by solid-liquid separation, preferably filtration, optionally subsequent washing with a solvent or a solvent mixture, preferably ether, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T2, preferably 30° C to 95° C, more preferably 70° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorida bezvodnog pomoću separacije kruto-tekuće, poželjno filtracijom, proizvoljno uz naknadno ispiranje sa otapalom ili smjesom otapala, poželjno eterom, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T2, poželjno 30° C do 95° C, poželjnije 70° C.
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably water, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T2, preferably 30° C to 95° C, more preferably 70° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid hidrata uz separaciju kruto-tekuće, poželjno uz filtraciju, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno u vodi, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T2, poželjno 30° C do 95° C, poželjnije 70° C.
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably ethanol, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T2, preferably 30° C to 95° C, more preferably 70° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid hidrata sa separacijom kruto-tekuće, poželjno filtracijom, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno etanolu, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T2, poželjno 30° C do 95° C, poželjnije 70° C.
heating up the resulting dispersion of step (b) to elevated temperature T1, preferably 30° C to 95° C, more preferably 60° C, optionally under stirring, optionally solid-liquid separating, preferably filtrating it to yield a solution, incubating the solution at room temperature until crystallization begins and further incubating it at room temperature for one or more hours or days, optionally under stirring, 
zagrijavanje nastale disperzije iz koraka (b) na povišenoj temperaturi T1, poželjno 30° C do 95° C, poželjnije 60° C, proizvoljno uz miješanje, proizvoljno uz separaciju kruto-tekuće, poželjno uz filtriranje da se dobije otopina, te inkubaciju otopine kod sobne temperature do početka kristalizacije i daljnju inkubaciju na sobnoj temperaturi, jedan ili više sati ili dana, proizvoljno uz miješanje,
dispersing the resulting dried crystals of step (d) in a solvent or a solvent mixture, preferably methanol or ethanol, and incubating the resulting dispersion at room temperature for one or more hours or days, optionally under stirring, 
dispergiranje dobivenih suhih kristala iz koraka (d) u otapalu ili smjesi otapala, poželjno u metanolu ili etanolu, te inkubaciju dobivene disperzije na sobnoj temperaturi, jedan ili više sati ili dana, proizvoljno uz miješanje,
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably ethanol, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T3, preferably 30° C to 95° C, more preferably 70° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid hidrata uz separaciju kruto-tekuće, poželjno uz filtraciju, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno u etanolu, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T3, poželjno 30° C do 95° C, poželjnije 70° C.
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride monohydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably acetone or THF, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T3, preferably 30° C to 95° C, more preferably 50° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid monohidrata uz separaciju kruto-tekuće, poželjno uz filtraciju, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno s acetonom ili THF, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T3, poželjno 30° C do 95° C, poželjnije 50° C.
converting 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (free base) or one or more salts thereof into the corresponding hydrochloride salt by addition of aqueous hydrochloric acid solution, optionally under stirring, heating up the resulting dispersion to elevated temperature T1, preferably 30° C to 100° C, more preferably 80° C to 100° C, optionally under stirring, and optionally solid-liquid separating, preferably filtrating it to obtain a solution, 
pretvaranje 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitrila (slobodna baza) ili jedne ili više njegovih soli u odgovarajuću hidrokloridnu sol dodavanjem vodene otopine klorovodične kiseline, proizvoljno uz miješanje, zagrijavanje nastale disperzije na povišenoj temperaturi T1, poželjno 30° C do 100° C, poželjnije 80° C do 100° C, proizvoljno uz miješanje, te uz separaciju kruto-tekuće, poželjno uz njenu filtraciju da se dobije otopina,
heating up again the resulting filtrate of step (b) to elevated temperature T2, preferably 30° C to 100° C, more preferably 78° C to 85° C, optionally under stirring, and subsequently cooling it down, preferably to 0° C to 40° C, more preferably to 0° C to 27° C, over one or more hours or days, optionally under stirring, and optionally cooling it further down, preferably to 0° C to 25° C, more preferably to 20° C, optionally under stirring, 
ponovno zagrijavanje dobivenog filtrata iz koraka (b) na povišenoj temperaturi T2, poželjno 30° C do 100° C, poželjnije 78° C do 85° C, proizvoljno uz miješanje, te naknadno hlađenje, poželjno na 0° C do 40° C, poželjnije na 0° C do 27° C, tijekom jednog ili više sati ili dana, proizvoljno uz miješanje, i proizvoljno daljnje hlađenje, poželjno na 0° C do 25° C, poželjnije na 20° C, proizvoljno uz miješanje,
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride monohydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably water, THF or acetone, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T3, preferably 30° C to 95° C, more preferably 50° C to 55° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid monohidrata sa separacijom kruto-tekuće, poželjno filtracijom, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno u vodi, THF ili acetone, i proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T3, poželjno 30° C do 95° C, poželjnije 50° C do 55° C.
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride anhydrate by solid-liquid separation, preferably filtration, optionally subsequent washing with a solvent or a solvent mixture, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T2, preferably 30° C to 95° C, more preferably 65° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorida bezvodnog uz separaciju kruto-tekuće, poželjno uz filtraciju, proizvoljno uz naknadno ispiranje sa otapalom ili smjesom otapala, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T2, poželjno 30° C do 95° C, poželjnije 65° C.
The solid formulation according to any one of claims 2 to 3, characterized in that the binder is selected from the group consisting of polyvidone/povidone, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch and gelatine. 
Kruti pripravak prema zahtjevu 1 ili 2, naznačen time, da je vezivo odabrano iz skupine koju čine polividon/povidon, metilceluloza, hidroksipropilmetilceluloza (HPMC), hidroksimetilceluloza, škrob i želatina.
The LTE network of claim 6, wherein the SGW is configured to send the special data packet to the source eNB after the SGW performs a path switching, wherein the special data packet is generated by the SGW; and the source eNB is configured to send a regenerated special data packet to the target eNB, wherein the regenerated special data packet is regenerated by the source eNB according to the special data packet sent by the SGW, and carries a PDCP sequence number of a next user data packet to be sent by the source eNB. 
LTE mreža prema zahtjevu 5, naznačena time da je SGW konfiguriran da generira poseban paket podataka i šalje poseban paket podataka prema izvorišnom eNB nakon što SGW provede komutaciju puta; i izvorišni eNB je konfiguriran da regenerira specijalni paket podataka sa završnom oznakom u skladu sa posebnim paketom podataka poslanim od SGW i šalje regenerirani posebni paket podataka prema ciljnom eNB, pri čemu regenerirani posebni paket podataka ne sadrži pakete korisničkih podataka i nosi broj PDCP sekvence slijedećeg paketa korisničkih podataka koji se treba poslati od izvornog eNB.
A pharmaceutical composition comprising a compound of any one of the preceding Claims, or a single stereoisomer, racemate, mixture of enantiomers and diastereomers, or geometric isomer thereof, optionally as a pharmaceutically acceptable salt of solvate thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. 
Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva, ili njegov tautomer, pojedinačni stereoizomer, racemat, smjesu enantiomera i diastereomera, ili geometrijski izomer, izborno kao njegova farmaceutski prihvatljiva sol ili solvat, i farmaceutski prihvatljiv nosač, inertni punitelj ili razblaživač.
The compound of any one of Claims 1 to 6, or a single stereoisomer, racemate, mixture of enantiomers and diastereomers, or geometric isomer thereof, optionally as a pharmaceutically acceptable salt of solvate thereof, for use in medicine. 
Spoj prema bilo kojem od patentnih zahtjeva 1-4, ili njegov tautomer, pojedinačni stereoizomer, racemat, smjesa enantiomera i diastereomera, ili geometrijski izomer, izborno kao njegova farmaceutski prihvatljiva sol ili solvat za uporabu u medicini.
Wind turbine according to claims 1-5, characterised in that the bearing (6) is a two-row conical roller bearing or a three-row roller bearing. 
Vjetroturbina prema zahtjevima 1-5, naznačena time što je ležište (6) dvoredno konično valjkasto ležište ili troredno valjkasto ležište.
Use of the compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of cancer, where the cancer is selected from breast cancer, Non-Hodgkins lymphoma, pancreatic cancer, hepatocellular cancer, gastric cancer, prostate cancer and lung cancer. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje raka, gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
The compound according to claim 10 for use in the treatment of cancer where the cancer is selected from breast cancer, Non-Hodgkins lymphoma, pancreatic cancer, hepatocellular cancer, gastric cancer, prostate cancer and lung cancer. 
Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
The compound according to claim 10 for use in the treatment of breast cancer. 
Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka dojke.
A process for the preparation of the compound claimed in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises the reaction of an acid of Formula (II) with (S)-3-amino-3-(4-chlorophenyl)propan-1-ol: wherein P1 represents a suitable protecting group; and thereafter, if necessary: removing the protecting group; and/or forming a pharmaceutically acceptable salt thereof. 
Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži reakciju kiseline Formule (II) i (S)-3-amino-3-(4-klorofenil)propan-1-ola: [image] pri čemu P1 predstavlja pogodnu zaštitnu skupinu; te nakon toga, ako je potrebno: uklanjanje zaštitne skupine; i/ili tvorbu njegove farmaceutski prihvatljive soli.
The use of claim 1, wherein the GI cleanser and the rifaximin result in adequate relief of one or more of IBS symptoms, abdominal pain symptoms, or bloating symptoms in about 35 - about 70% of subjects administered the GI cleanser and the rifaximin. 
Uporaba prema zahtjevu 1, naznačena time da pripravak za gastrointestinalno čišćenje i rifaksimin rezultiraju sa adekvatnim olakšanjem jednog ili više simptoma upalne bolesti crijeva, simptoma abdominalne boli, ili simptoma nadutosti u oko 35 do oko 70% subjekata kojima se daju pripravak za gastrointestinalno čišćenje i rifaksimin.